Global Human Albumin Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Albumin Market Research Report 2024
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
According to Mr Accuracy reports’s new survey, global Human Albumin market is projected to reach US$ 6954 million in 2034, increasing from US$ 5132.1 million in 2022, with the CAGR of 4.5% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Albumin market research.
Human albumin was initially used only as a volume replacement therapy; however, extensive research has shown that human albumin has numerous applications in other therapeutic areas as well. For instance, Grifols is exploring the use of the product to stabilize Alzheimer’s disease. Moreover, drugs containing human serum albumin, such as Levemir and Abraxane are used to treat diabetes and metastatic breast cancer, respectively. Furthermore, the on-going research and augmented adoption of albumin in the new therapeutic areas will boost this market’s growth during the predicted period.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Albumin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Segment by Type
5% Concentrations
25% Concentrations
Others
Therapeutics
Drug Formulation & Vaccine
Component of Media
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Human Albumin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Human Albumin market is projected to reach US$ 6954 million in 2034, increasing from US$ 5132.1 million in 2022, with the CAGR of 4.5% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Albumin market research.
Human albumin was initially used only as a volume replacement therapy; however, extensive research has shown that human albumin has numerous applications in other therapeutic areas as well. For instance, Grifols is exploring the use of the product to stabilize Alzheimer’s disease. Moreover, drugs containing human serum albumin, such as Levemir and Abraxane are used to treat diabetes and metastatic breast cancer, respectively. Furthermore, the on-going research and augmented adoption of albumin in the new therapeutic areas will boost this market’s growth during the predicted period.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Albumin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Segment by Type
5% Concentrations
25% Concentrations
Others
Segment by Application
Therapeutics
Drug Formulation & Vaccine
Component of Media
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Human Albumin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source